Free Trial
→ New crypto boom will be greatest in history (From Banyan Hill Publishing) (Ad)

Vaxcyte Q4 2022 Earnings Report

Vaxcyte logo
$88.32 -3.63 (-3.95%)
As of 01/31/2025 04:00 PM Eastern
Earnings HistoryForecast

Vaxcyte EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Vaxcyte Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxcyte Announcement Details

Quarter
Q4 2022
Date
2/27/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Powered by Quartr

Vaxcyte Earnings Headlines

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
January 30 at 4:15 PM | globenewswire.com
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
January 30 at 11:51 AM | globenewswire.com
The Shadow President?
President Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn from the World Health Organization... exited the Paris climate accord... and begun dismantling many Federal programs... But there's ONE executive order that could go down in history as the most important of all.
February 1, 2025 | Altimetry (Ad)
Vaxcyte president and CFO sells shares worth $692,100
January 22, 2025 | msn.com
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?
January 18, 2025 | msn.com
Vaxcyte’s VAX-A1 Vaccine: A Promising Contender in the Global Fight Against Group A Strep
January 15, 2025 | markets.businessinsider.com
See More Vaxcyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email.

About Vaxcyte

Vaxcyte (NASDAQ:PCVX), a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

View Vaxcyte Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles